Towards a vaccine against Ebola virus

Thomas Geisbert, Peter B. Jahrling

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.

Original languageEnglish (US)
Pages (from-to)777-789
Number of pages13
JournalExpert Review of Vaccines
Volume2
Issue number6
DOIs
StatePublished - Dec 2003
Externally publishedYes

Fingerprint

Ebola Vaccines
Ebolavirus
Ebola Hemorrhagic Fever
Vaccines
Bioterrorism
Quarantine
Active Immunotherapy
Weapons
USSR
Primates
Disease Outbreaks
Fever
Mortality

Keywords

  • Ebola virus
  • Filoviridae
  • Filovirus
  • Pathogenesis
  • Vaccines
  • Viral vaccines

ASJC Scopus subject areas

  • Immunology
  • Pharmacology

Cite this

Towards a vaccine against Ebola virus. / Geisbert, Thomas; Jahrling, Peter B.

In: Expert Review of Vaccines, Vol. 2, No. 6, 12.2003, p. 777-789.

Research output: Contribution to journalArticle

Geisbert, Thomas ; Jahrling, Peter B. / Towards a vaccine against Ebola virus. In: Expert Review of Vaccines. 2003 ; Vol. 2, No. 6. pp. 777-789.
@article{5f92af9319314451855eef24fa25862f,
title = "Towards a vaccine against Ebola virus",
abstract = "Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.",
keywords = "Ebola virus, Filoviridae, Filovirus, Pathogenesis, Vaccines, Viral vaccines",
author = "Thomas Geisbert and Jahrling, {Peter B.}",
year = "2003",
month = "12",
doi = "10.1586/14760584.2.6.777",
language = "English (US)",
volume = "2",
pages = "777--789",
journal = "Expert Review of Vaccines",
issn = "1476-0584",
publisher = "Expert Reviews Ltd.",
number = "6",

}

TY - JOUR

T1 - Towards a vaccine against Ebola virus

AU - Geisbert, Thomas

AU - Jahrling, Peter B.

PY - 2003/12

Y1 - 2003/12

N2 - Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.

AB - Ebola virus infection causes hemorrhagic fever with high mortality rates in humans and nonhuman primates. Currently, there are no vaccines or therapies approved for human use. Outbreaks of Ebola virus have been infrequent, largely confined to remote locations in Africa and quarantine of sick patients has been effective in controlling epidemics. In the past, this small global market has generated little commercial interest for developing an Ebola virus vaccine. However, heightened awareness of bioterrorism advanced by the events surrounding September 11, 2001, concomitant with knowledge that the former Soviet Union was evaluating Ebola virus as a weapon, has dramatically changed perspectives regarding the need for a vaccine against Ebola virus. This review takes a brief historic look at attempts to develop an efficacious vaccine, provides an overview of current vaccine candidates and highlights strategies that have the greatest potential for commercial development.

KW - Ebola virus

KW - Filoviridae

KW - Filovirus

KW - Pathogenesis

KW - Vaccines

KW - Viral vaccines

UR - http://www.scopus.com/inward/record.url?scp=0348110381&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348110381&partnerID=8YFLogxK

U2 - 10.1586/14760584.2.6.777

DO - 10.1586/14760584.2.6.777

M3 - Article

VL - 2

SP - 777

EP - 789

JO - Expert Review of Vaccines

JF - Expert Review of Vaccines

SN - 1476-0584

IS - 6

ER -